Filing Details
- Accession Number:
- 0001214659-23-016015
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-04 20:50:44
- Reporting Period:
- 2023-11-30
- Accepted Time:
- 2023-12-04 20:50:44
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1138723 | Accuray Inc | ARAY | Surgical & Medical Instruments & Apparatus (3841) | 208370041 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1927594 | Ali Pervaiz | 1310 Chesapeake Terrace Sunnyvale CA 94089 | Svp Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-11-30 | 132,075 | $0.00 | 418,322 | No | 4 | A | Direct | |
Common Stock | Disposition | 2023-12-01 | 13,463 | $2.47 | 404,859 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- This represents a Restricted Stock Unit grant with a grant date of 11/30/2023 that vest annually over three years from grant date.
- Includes 2,500 shares acquired on November 30, 2023 under the Accuray Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c).
- Adjusted to remove shares related to Performance Stock Unit grants erroneously reported on Table I on December 7, 2022.
- Shares were automatically sold in accordance with Accuray policy for all restricted stock unit (RSU) releases in order to cover tax obligations upon RSU release and is consistent with Accuray practices for all RSU releases of employees located in the United States.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.4707 to $2.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.